Skip to content
Spiritual Quotes – Lifestyle
Author:
Kali Therapeutics
Kali Therapeutics Named to the 2026 Endpoints 11, Recognizing Biotech’s Most Promising Startups
September 25, 2026
Kali Therapeutics Receives U.S. FDA Clearance for KT501 Investigational New Drug Application
September 3, 2026
Kali Therapeutics Announces Poster Presentation of KT209, a Novel CD19 x CD20 x CD3 Trispecific Antibody, at the EHA 2026 Annual Congress
June 8, 2026
Kali Therapeutics Announces Oral Presentation of KT502, a Novel CD19 x CD3 T-Cell Engager, at the EULAR 2026 Annual Congress
May 18, 2026